Dobec M, Jung M, Zupancić-Salek S, Burek V, Mihaljević I, Grgicević D
Institut Virion, Zürich, Svicarska.
Lijec Vjesn. 1993 May-Jun;115(5-6):142-5.
Serums of whole blood donors, plasma donors, hemophiliacs, persons with risks behavior and normal population simultaneously were tested for markers of infectious diseases, anti-HIV-1 with Plivazim and anti-HIV-1/2 and anti-HTLV-1/2 with Roche Retrovirus EIA. The positive results were confirmed by immunofluorescence assay and Western blot. Nonspecific reactive serums were detected by Roche Retrovirus EIA and by Plivazim EIA, but there was no significant difference in the frequence of reactive results. Roche Retrovirus EIA test had specificity of 99.16% and sensibility of 97.56% as compared to Plivazim. Simultaneous testing of donors with a combined test for anti-HIV-1/2 and anti-HTLV-1 is equally reliable as testing with only anti-HIV-1.
同时对全血捐献者、血浆捐献者、血友病患者、有危险行为者和正常人群的血清进行传染病标志物检测，使用Plivazim检测抗HIV-1，使用罗氏逆转录病毒酶免疫测定法检测抗HIV-1/2和抗HTLV-1/2。阳性结果通过免疫荧光测定法和蛋白质印迹法进行确认。通过罗氏逆转录病毒酶免疫测定法和Plivazim酶免疫测定法检测到非特异性反应血清，但反应结果的频率没有显著差异。与Plivazim相比，罗氏逆转录病毒酶免疫测定法的特异性为99.16%，敏感性为97.56%。对抗HIV-1/2和抗HTLV-1进行联合检测的捐献者与仅检测抗HIV-1同样可靠。
